盘面上，现货黄金首次站上5200美元，贵金属、黄金板块继续爆发，中金黄金、赤峰黄金等十余股涨停；有色金属板块掀涨停潮，白银有色、常铝股份等多 股涨停；转基因板块拉升，农发种业涨停；汽车拆解板块走高，飞南资源20CM涨停；钛白粉、煤化工及磷化工等板块涨幅居前。另外，生物疫苗、痘病毒 防治板块下挫，百普赛斯跌逾10%；医疗器械板块走低，之江生物跌逾8%；光伏社板块走弱，高测股份跌逾8%；航天航空、装修装饰及CRO等板块跌幅居 前。(格隆汇) | 上证指数 | 深证成指 | 北证5( | | --- | --- | --- | | 4151.24 | 14342.89 | 1562.4 | | +11.33 +0.27% +12.99 +0.09% -2.49 -0 | | | | 科创50 | 创业板指 | 万得全/ | | 1554.80 | 3323.56 | 6863.2 | | -1.17 -0.08% -19.04 -0.57% +7.43 +0 | | | | 沪深300 | 中证500 | 中证A5( | | 4717.99 | 8601.16 | 5951.1 | | +12.30 +0.26% ...

（责任编辑：刘畅 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com A股今日集体上涨，截至收盘，沪指涨0.18%，深成指涨0.09%，创业板指涨0.71%，北证50指数跌 0.05%，沪深京三市成交额29215亿元，较上日缩量3592亿元，三市超1900只个股飘红。 板块题材上， 贵金属、半导体、培育钻石、光伏设备、保险、军工装备、CPO、AI语料板块涨幅居前；生物疫苗、煤 炭开采加工、化学化工、电池、猪肉、白酒、旅游及酒店、电网设备板块跌幅居前。 ETF方面，半导体板块强势走高，华泰柏瑞基金中韩半导体ETF、华夏基金科创半导体ETF、华泰 柏瑞基金科创半导体设备ETF分别涨4.51%、3.59%、3.52%。科创100指数午后拉升，国泰基金科创板 100ETF涨3.41%。CPO板块久违反弹，创业板人工智能ETF华宝涨2.76%。 国证2000ETF工银跌4.93%。疫苗板块走低，疫苗ETF、疫苗ET ...

A股三大指数涨跌互现，截至午间收盘，沪指涨0.03%报4134.03点，深成指跌0.37%，创业板指涨 0.44%，北证50指数跌1.26%。沪深京三市半日成交额18905亿元，较上日缩量3726亿元，全市场超3700 只个股下跌。盘面上，现货黄金昨日强势突破5100美元关口，黄金股再度活跃，湖南黄金、紫金矿业等 一众股创历史新高；保险、半导体、CPO、培育钻石等板块走强，生物疫苗、养殖业、电池等板块跌幅 居前。 ...

Core Viewpoint - The A-share market experienced fluctuations with significant movements in various sectors, particularly in precious metals and biotechnology, while the commercial aerospace sector faced a sharp decline [1][12]. Group 1: A-share Market Overview - The Shanghai Composite Index closed at 4132.61 points, down 0.09%, while the Shenzhen Component and ChiNext Index fell by 0.85% and 0.91%, respectively [1]. - A total trading volume of approximately 3.28 trillion yuan was recorded, an increase of over 160 billion yuan from the previous day [1]. - Over 3700 stocks in the A-share market closed in the red, with notable declines in the commercial aerospace and semiconductor sectors [1]. Group 2: Precious Metals Sector - The precious metals sector showed strong performance, with silver and gold stocks gaining significantly. Silver Youse rose to a 5-day limit, while companies like Hunan Gold and Zhaojin Gold also hit the limit [3][4]. - Spot gold prices reached a historic high of $5100 per ounce, driven by factors such as moderate U.S. inflation data and geopolitical uncertainties [5]. - Institutional analysis indicates that the ongoing rise in gold prices is supported by increased investment demand and central bank purchases, suggesting a robust long-term outlook for gold and silver [5]. Group 3: Biotechnology Sector - The biotechnology sector saw a surge, with companies like Hualan Biological and Jindike hitting the 20% limit, and others like Zhifei Biological rising nearly 15% [7][8]. - The rise in the sector is partly attributed to the emergence of the Nipah virus in India, prompting increased demand for related testing products [9][10]. Group 4: Commercial Aerospace Sector - The commercial aerospace sector experienced a significant drop, with companies like Shaoyang Hydraulic and Haoshi Electromechanical falling by approximately 14% [12]. - China Satellite issued a risk warning, indicating that its stock price had risen significantly without fundamental changes, highlighting the risks of market speculation [12][14].

Group 1 - The core viewpoint of the article highlights that the Chinese pharmaceutical industry is at the starting point of a global value reassessment, as emphasized during the JPM conference [1] - The domestic CXO industry is transitioning from a "cost advantage" model to a dual-driven approach of "technology + scale," leveraging capabilities in areas such as ADC, dual antibodies, and GLP-1 to evolve from "intermediate suppliers" to "global innovation enablers" [1] - There is a noticeable acceleration in the globalization of domestic pharmaceutical companies, with key trends including the iteration of technology platforms like ADC, multi-antibodies, and small nucleic acids, as well as significant transactions exceeding $10 billion with multinational corporations (MNCs) [1] Group 2 - The year 2026 is identified as a critical milestone for domestic pharmaceutical companies, marking a period of intensive verification of transformation effectiveness, with many companies initiating global registration studies, key data readouts, and new product applications [1] - The vaccine ETF (159643) tracks the vaccine biotechnology index (980015), which focuses on bioproducts, vaccine research and development, and related services, reflecting the overall performance of listed companies engaged in vaccine production, research, and sales [1]

盘面上，大金融板块护盘，券商、保险等方向领涨；资源股强势，其中，有色、贵金属概念持续爆发， 四川黄金等多股涨停，煤炭、油气板块走强，中国海油创历史新高，中国神华等股走高；化工板块拉 升，红宝丽涨停；生物疫苗、抗病毒、流感等医药股全线上涨，华兰疫苗等多股涨停。下跌方面，热门 板块和个股集体杀跌，半导体芯片、商业航天、机器人、AI应用等方向跌幅居前，中国卫星触及跌 停；此外，白酒板块下挫，洋河股份创8年多新低。 展望后市，中信证券认为，市场信心持续恢复过程中，只要在相对低位、能讲出逻辑且不在宽基权重的 行业预计都可能将修复。 从个股看，两市上涨1604家，下跌3771家，98家涨幅持平。两市共79股涨停，共42股跌停。 今日市场放量震荡，三大指数集体收跌，创业板指、科创50指数调整明显。市场连续两个交易日成交超 3万亿，较上个交易日放量超千亿，两市下跌个股超3700只。 截至收盘，沪指跌0.09%报4132.61点，成交14519亿元；深成指跌0.85%报14316.64点，成交17964亿 元。创业板指下跌0.91%，报3319.15点。 据券商中国，代表风险偏好的两大变量集体来袭。一是地缘风险加剧和美元指数杀 ...

Market Overview - The three major A-share indices collectively declined, with the Shanghai Composite Index down 0.09% to 4132 points, the Shenzhen Component Index down 0.85%, and the ChiNext Index down 0.91% [1] - The total market turnover reached 3.28 trillion yuan, an increase of 162.5 billion yuan compared to the previous trading day, with over 3700 stocks declining [1] Sector Performance - Precious metals and gold concepts surged, with multiple stocks such as Xiaocheng Technology, Western Gold, and Hunan Silver hitting the daily limit [1] - The outbreak of the Nipah virus in India led to a rise in the biopharmaceutical sector, with stocks like Cap Bio also hitting the daily limit [1] - The non-ferrous metals sector saw gains, with stocks like Xingye Silver and Tin also reaching the daily limit [1] - The oil, insurance, and influenza sectors performed well, showing significant gains [1] - Conversely, the commercial aerospace and satellite internet sectors experienced a sharp decline, with stocks like China Satellite and Aerospace Development hitting the daily limit [1] - The 6G concept sector fell, with Yaguang Technology dropping over 13% [1] - The military industry sector also declined, with stocks like Chaojie Co. falling over 10% [1] - Sectors such as LiDAR, AI chips, and humanoid robots faced significant losses [1] Fund Inflow and Performance - The top sectors by net fund inflow included oil and gas (+7.30%), precious metals (+5.03%), and basic materials (+2.72%) [2] - Other sectors showing positive performance included coal (+2.61%), energy equipment (+2.36%), and the internet sector (+1.89%) [2]

Core Insights - The vaccine industry is entering a deep transformation period characterized by stock competition and structural adjustments, where differentiated innovation is crucial for companies to navigate through cycles [1] - Zhifei Biological, a leader in the domestic biological vaccine sector, is facing challenges due to a decline in industry overall prosperity by 2025, driven by reduced public vaccination willingness and intensified market competition [1] - The company anticipates a temporary net profit loss for the year, reflecting the industry's deep reshuffling [1] Company Strategies - In response to performance pressures, Zhifei Biological is taking proactive measures, including recognizing inventory and accounts receivable impairments to accurately reflect its financial status, thereby laying a solid foundation for future development [1] - The company has secured over 10 billion yuan in loans from financial institutions, guaranteed by its actual controller, to optimize operational capacity and restructure existing debts, reinforcing its financial stability [1] - Zhifei Biological is adjusting procurement plans with partners in its traditional vaccine agency line to alleviate upstream supply pressures while enhancing marketing strategies to accelerate inventory turnover [1] Research and Development - The company has over 40 products in its research pipeline, with several, including the diploid rabies vaccine and 15-valent pneumonia conjugate vaccine, currently under review for market approval, indicating significant market potential [2] - Zhifei Biological's self-developed products, such as the quadrivalent influenza virus split vaccine and the 26-valent pneumonia conjugate vaccine, have achieved notable breakthroughs, showcasing its technological leadership [2] - The company is committed to a differentiated competitive strategy focused on technological innovation and product iteration, which is expected to help it navigate the industry's adjustment cycle effectively [2]

Core Viewpoint - The controlling shareholder of Inner Mongolia Biological Co., Ltd. plans to increase its stake in the company by no less than RMB 50 million and no more than RMB 100 million within the next 12 months, without setting a fixed price or price range, demonstrating confidence in the company's long-term intrinsic value and a commitment to face market fluctuations together with all shareholders [1]. Group 1 - The announcement of the share buyback plan reflects the culmination of years of efforts to resolve governance issues within the company [1]. - The previous failed fundraising attempt in 2022 due to pricing disputes highlighted the challenges posed by a dispersed shareholding structure, which ultimately led to a governance transformation [2]. - The successful implementation of a new fundraising plan in 2024, with a share price of RMB 14.25, marked a 113% increase from the previously rejected price of RMB 6.69, establishing a new value benchmark for the company [2]. Group 2 - The strategic evolution from a failed low-price fundraising attempt in 2022 to a successful high-price issuance in 2024, followed by an unlimited market buyback in 2025, illustrates a clear strategic loop for the company [3]. - The controlling shareholder's decision to conduct an unconditional buyback without a price range signifies a shift towards long-term value creation based on solid governance [3].

Group 1 - The event "Central Radio and Television Finance Annual Dialogue 2025" focuses on the theme "Setting Sail for the 14th Five-Year Plan with New Momentum" to gather insights and build connections among government, industry, academia, and finance [1][3] - Approximately 300 representatives from various sectors participated, discussing the construction of a modern industrial system and strengthening the foundation of the real economy [1][3] - The dialogue aims to enhance industrial collaboration and address challenges while promoting economic stability and growth [3] Group 2 - Former Vice Chairman of the National Social Security Fund Wang Zhongmin highlighted that the registration system has significantly boosted the prosperity of China's capital market, which will further facilitate the cultivation of new productive forces during the 14th Five-Year Plan [4] - Former Vice Minister of Commerce Wei Jianguo emphasized that service consumption will play a crucial role in expanding domestic demand and will be a key strategy for economic recovery [5] - Tsinghua University’s Professor He Ping stated that a stable and efficient financial system is essential for supporting technological innovation and addressing related challenges [6] Group 3 - Shenyin Wanguo Securities' Chairman Zhou Haichen discussed four new requirements for the capital market during the 14th Five-Year Plan: serving new productive forces, managing household wealth, building a strong financial nation, and achieving high-level financial openness [8] - Former Deputy Secretary-General of the National Development and Reform Commission Fan Hengshan stressed the importance of understanding the relationship between the development of new productive forces and strategic requirements, development measures, and environmental factors [10] - Shenzhen Stock Exchange's Vice General Manager Li Mingzhong expressed the need for a positive interaction among regulation, market, and media to create a conducive environment for capital market development [12] Group 4 - Shanghai Jiao Tong University’s Chairman Tu Guangshao pointed out that financial services must evolve to keep pace with changes in the real economy and new forms of development [14] - The dialogue included discussions on green development, industrial transformation, and health service optimization, emphasizing the importance of these areas for new productive force cultivation [16] - The session on advanced manufacturing transformation focused on digital energy innovation and the integration of intelligent technologies, outlining practical paths and opportunities for development [18] Group 5 - The dialogue on the big health industry innovation highlighted discussions on vaccine research, immune management, and smart health hardware applications, contributing to the construction of a healthy China [20] - A report on county-level credit construction and high-quality development was released, providing theoretical support and practical guidance for local economic development [21] - The collaboration between Shenzhen Stock Exchange and Central Radio and Television Network aims to enhance the multi-layered bond market and support the development of new productive forces [24]